SAN FRANCISCO, March 27, 2017 /PRNewswire/ -- Twist Bioscience, a company accelerating science and innovation through rapid, high-quality DNA synthesis, today announced that it raised an additional $33 million. To date, Twist Bioscience has raised a total of $166 million.
“It is an exciting time to be leading Twist Bioscience as we expand our reach and continue to deliver industry-leading gene volume to our customers, enabling innovative research in multiple market segments,” commented Emily M. Leproust, Ph.D., CEO of Twist Bioscience. “We welcome the additional equity capital to further accelerate growth of the core gene synthesis business, as well as pharmaceutical discovery and data storage vertical strategies.”
About Twist Bioscience
At Twist Bioscience, our expertise is accelerating science and innovation by leveraging the power of scale. We have developed a proprietary semiconductor-based synthetic DNA manufacturing process featuring a high throughput silicon platform capable of producing synthetic biology tools, including genes, oligonucleotide pools and variant libraries. By synthesizing DNA on silicon instead of on traditional 96-well plastic plates, our platform overcomes the current inefficiencies of synthetic DNA production, and enables cost-effective, rapid, high-quality and high throughput synthetic gene production, which in turn, expedites the design, build and test cycle to enable personalized medicines, pharmaceuticals, sustainable chemical production, improved agriculture production, diagnostics and biodetection. We are also developing new technologies to address large scale data storage. For more information, please visit www.twistbioscience.com. Twist Bioscience is on Twitter. Sign up to follow our Twitter feed @TwistBioscience at https://twitter.com/TwistBioscience.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/twist-bioscience-raises-33-million-300429499.html
SOURCE Twist Bioscience
